This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Evidence-Based Medicine  • Statistics and Research Methods  • Alert me on articles by topic

Arch Neurol. 1999;56:524.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THERAPEUTIC NIHILISM is no longer an apt caricature of neurology. We now read regularly of therapeutic advances in all fields of neurology. The therapeutics of neurologic disorders have become a common theme at professional meetings and a pervasive topic of scientific reports. Advertisements of neurologic therapies abound. Most rewarding is the positive impact that neurotherapeutic advances have made on morbidity, mortality, and quality of life of our patients and families. It is a fitting time for Archives of Neurology to devote a regular section to Neurotherapeutics.

The evolution of evidence-based medicine has defined new rules for sound clinical practice grounded in controlled research data and outcomes. The science of medicine is a necessary complement to the art of medicine. In the area of therapeutics, random allocation of research participants to adequately concealed interventions and the systematic measurement of clinically relevant outcomes are at the core of evidence-based medicine. The ARCHIVES . . . [Full Text of this Article]

RELATED ARTICLE

Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
Stanley Fahn
Arch Neurol. 1999;56(5):529-535.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Experimental Neurotherapeutics: Leaps and Bounds
Shoulson
Arch Neurol 2002;59:689-691.
FULL TEXT